177 research outputs found
A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans
Prostate-specific antigen (PSA) is a kallikrein-like serine protease,
which is almost exclusively synthesized in the luminal epithelial cells of
the human prostate. PSA expression is androgen regulated. Previously, we
characterized in vitro the proximal promoter, and a strong enhancer
region, approximately 4 kb upstream of the PSA gene. Both regions are
needed for high, androgen-regulated activity of the PSA promoter in LNCaP
cells. The goal of the present study is the in vivo characterization of
the PSA promoter. Three transgenic mouse lines carrying the Escherichia
coli LacZ gene, driven by the 632-bp proximal PSA promoter, and three
lines with LacZ, driven by the 6-kb PSA promoter, were generated.
Expression of the LacZ reporter gene was analyzed in a large series of
tissues. Transgene expression could not be demonstrated in any of the
transgenic animals carrying the proximal PSA promoter. All three lines
carrying the 6-kb PSA promoter showed lateral prostate-specific
beta-galactosidase activity. Transgene expression was undetectable until 8
weeks after birth. Upon castration, beta-galactosidase activity rapidly
declined. It could be restored by subsequent androgen administration. A
search for mouse PSA-related kallikrein genes expressed in the prostate
led to the identification of mGK22, which was previously demonstrated to
be expressed in the submandibular salivary gland. Therefore, the 6-kb
PSA-LacZ transgene followed the expression pattern of the PSA gene in
humans, which is almost completely prostate-specific, rather than that of
mGK22 in mice. In conclusion, the 6-kb promoter fragment appears to
contain most, if not all, information for androgen regulation and prostate
specificity of the PSA gene
Recent advances in the development of animal and cell culture models for prostate cancer research: A minireview
A Multilevel Product Model for Simulation-Based Design of Mechanical Systems
This paper presents a multilevel product model that supports Simulation-Based Design (SBD) of mechanical systems, from pre liminary to detailed design stages The pnmary goal of the SBD is to achieve product designs featuring better performance and greater du rability and reliability through computer-based modeling, engineering analysis, and design trade-off. A Computer-Aided Design (CAD) model combined with engineering parameters and mathematical equations that simulate physical behavior of the mechanical system constitute its product model for SBD. For preliminary design, improvement of system performance, including dynamics and human factors, is usually the primary focus A CAD model with reasonably accurate physical parameters, such as mass properties of major components or assemblies, is defined as the base definition of the product model for SBD. A number of simulation models are derived from the base definition to sup port simulation of the mechanical system performance A parametric study can be conducted to search for design alternatives using dimen sion parameters created in the parameterized CAD model. The CAD model and base definition are then refined from the preliminary design stage to support intermediate designs. Intermediate designs will primarily focus on product subsystem performance. A product model is evolved by refining geometric representation of mechanical components in CAD, and expanding product assembly into parts and sub assemblies for further engineering analysis Component designs for performance, such as fatigue, mechanical reliability, and structural per formance, as well as maintainability are the primary focus in the detailed design stage. A detailed product model evolved from that of the previous design is needed In the detailed design stage, a systematic design trade-off method supports design improvement. A High Mobil ity Multi-Purpose Wheeled Vehicle (HMMWV) is employed to illustrate and demonstrate the proposed product model.Yeshttps://us.sagepub.com/en-us/nam/manuscript-submission-guideline
Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice
Galaxy Clusters Associated with Short GRBs. II. Predictions for the Rate of Short GRBs in Field and Cluster Early-Type Galaxies
We determine the relative rates of short GRBs in cluster and field early-type
galaxies as a function of the age probability distribution of their
progenitors, P(\tau) \propto \tau^n. This analysis takes advantage of the
difference in the growth of stellar mass in clusters and in the field, which
arises from the combined effects of the galaxy stellar mass function, the
early-type fraction, and the dependence of star formation history on mass and
environment. This approach complements the use of the early- to late-type host
galaxy ratio, with the added benefit that the star formation histories of
early-type galaxies are simpler than those of late-type galaxies, and any
systematic differences between progenitors in early- and late-type galaxies are
removed. We find that the ratio varies from R(cluster)/R(field) ~ 0.5 for n =
-2 to ~ 3 for n = 2. Current observations indicate a ratio of about 2,
corresponding to n ~ 0 - 1. This is similar to the value inferred from the
ratio of short GRBs in early- and late-type hosts, but it differs from the
value of n ~ -1 for NS binaries in the Milky Way. We stress that this general
approach can be easily modified with improved knowledge of the effects of
environment and mass on the build-up of stellar mass, as well as the effect of
globular clusters on the short GRB rate. It can also be used to assess the age
distribution of Type Ia supernova progenitors.Comment: ApJ accepted versio
New insights into the genetic etiology of Alzheimer's disease and related dementias
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele
Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment
Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. Methods: We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. Results: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. Conclusions: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study
Molecular-dynamics study of the dynamical excitations in commensurate monolayer films of nitrogen molecules on graphite: A test of the corrugation in the nitrogen-graphite potential
Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility
Genome-wide association studies (GWASs) have identified hundreds of loci associated with Crohn's disease (CD). However, as with all complex diseases, robust identification of the genes dysregulated by noncoding variants typically driving GWAS discoveries has been challenging. Here, to complement GWASs and better define actionable biological targets, we analyzed sequence data from more than 30,000 patients with CD and 80,000 population controls. We directly implicate ten genes in general onset CD for the first time to our knowledge via association to coding variation, four of which lie within established CD GWAS loci. In nine instances, a single coding variant is significantly associated, and in the tenth, ATG4C, we see additionally a significantly increased burden of very rare coding variants in CD cases. In addition to reiterating the central role of innate and adaptive immune cells as well as autophagy in CD pathogenesis, these newly associated genes highlight the emerging role of mesenchymal cells in the development and maintenance of intestinal inflammation.Large-scale sequence-based analyses identify novel risk variants and susceptibility genes for Crohn's disease, and implicate mesenchymal cell-mediated intestinal homeostasis in disease etiology.Cellular mechanisms in basic and clinical gastroenterology and hepatolog
- …